




# Practical Strategies For Conducting Clinical Trials in The Gambia

Dr. Ahmed Cherno Futa Clinical Trial Coordinator

# Background

- The MRC Gambia unit, has a 75-year history of operations in The Gambia
- Good relationship with the Ministry of Health and the Local communities.
- Currently 17 clinical trials are ongoing.
- Over the past 5 years, 29 clinical trials have been conducted across the country and within the subregion.

## Background



- The Brikama Local Government area has a population of 688,000
- 9 districts
- Brikama is located in the kombo central district with a population of 140,000
- Sensitization and recruitment reach surrounding communities

https://www.citypopulation.de/en/gambia/admin/3\_\_brikama/





#### **Brikama Trial Site**



- The trial site is located within the premises of the Brikama district hospital.
- Site was opened in 2017.
- 5 clinical trials have been hosted at this site
  - 1. Pneumosil phase 3 trial
  - 2. Pneumosil 2+1 trial
  - 3. Men ACXWY phase 3 trial
  - 4. Novel Oral polio 2 phase 3 trial
  - 5. Serum Institute yellow fever phase 3 trial
- Enrolled 3805 participants out of 7863 across these trials enrolled at this site.





## Strategies employed before the trial

#### Translation and audio recording of Information sheet

- •A team of experienced field staff translate the information sheet into multiple consent languages
- Audio recording is vetted by the communications department.
- •The audio recordings are not used during the consent process but serve as a reference for agreed translations during sensitization and consenting





# Strategies employed before the start of the trial

#### **Community Sensitization**


- Meetings with the "Alkalos" (village head), community stakeholders and potential participants in target recruitment areas.
- Meetings with officers in charge (OIC) in the health centers in and around Brikama.

Meetings	Communities	Health Facilities	Total
Done	52	25	77
Pending	1	0	1
Total	53	25	78





# **Community Sensitization**















#### **Community sensitization**

- Provides an opportunity to interact with the "Alkalo" (village head), religious leaders, womens groups and other stakeholders in target communities
- To introduce the study to the community, allowing opportunity for questions.
- Address rumors and misconceptions.
- Scout for impartial witnesses.
- Meetings with heads of health centers creates an enabling environment for our staff during individual sensitization.





#### Strategies employed when the trial starts

#### **Individual Sensitization**

- Strategy of Individual sensitization will depend on age of participants to be recruited
- Most of our studies involve infants and young children so we take advantage of immunization clinics
- Maintain a schedule of the immunization clinic days of health facilities in our target areas





# Strategies employed when the trial starts

#### **Individual Sensitization**

- Field staff conduct one-on-one sensitization with potential participants.
- Sensitization and consent occur on separate days.
- Participants take a copy of the information sheet home to discuss with family.
- Participant information is recorded on sensitization forms.
- Completed sensitization forms entered into the participant tracking database.







# Strategies employed when the trial starts

LEO27754/YWF:02		at I	SHTM
BRIKAMA	5	Sensitization Number	
Is the infant already enrolled in a	nother study? Yes	No	If YES - STOP
Does the parent/guardian have the	ne IWC in hand now? Yes	No L	If No - STOP
All details as written on IWC			
Name:			
Date of Birth:     /       Mother's	_//	Sex (M/F)	
Name:		لللللل	
Father's Name:			
Compound			
Head's Name:			
Vaccination History (from IWC) Yellow Fever	V-1	N-1 1	If YES -STOP
MR or MMR	Yes	No L	If YES-STOP
Men A			If YES-STOP
Men A	Yes	No L	IT YES-STOP
Other vaccination (in last 28 days  1.  2.	- complete below if "Yes")	Yes □   /         /	No 🗆
3.		VI I I VI I	
4.		1/1 1 1 1/1 1	
5.		VI I I VI I	
<b>0.</b>		PLLLPLL	
Contact numbers			
Africell:	Q-cell		
Gamcel:	Comiu	ım:	
Other numbers:	Or Or		
Study information			
Has the study been explained to		Yes	
	ent been given to the parent/guardian?		∐ No ∐
Write SENT SII-YFV on the top	of the IWC to indicate sensitization has	taken place.	
/ersion 1.1 11 Nov 2022			Page 1 of 2





Sensitizes to ensure that another than the sense that the sense that the sense than the sense than the sense that the sense	ation Number 21114	4519
ch information as possible to ensure that anot	- 12- WW - 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12-	
	her field worker or driver co	ould find the
70		
a health cartne of Compand next	po Strangh to the Iman	\$ 10 S
ed in taking part in the study?	Yes 📈	No
concerns raised?		
		a health Cartine go Strangh Compand next to the Iman Lir  ed in taking part in the study?  Yes IXI

#### Informed consent visit

- Participants greeted by senior field staff at reception.
- Participants details and eligibility is confirmed.
- Participant is matched with consenter and impartial witness based on the language.







#### Informed consent visit

			CHILD'S	No:		
CHILD'S INF	ORMATION					
irst Name		_				
amily Name						
Date of Birth					(DD/N	IM/YYY
Gender			Male	Fema	le	
Weight at Birth		_			kg	
Market Street			THE RELLEVA			
Birth Registration	No	=	7		е Пвва	THE LA
Place of Delivery		A STATE	Health Facility	Hom		
Attended by		BAR B	Trained Staff	TBA	Other	
Date First Seen						им/үүү
Mother's Name Father's Name Address (Village Tel: No:						
Father's Name Address (Village	JM EXAMIN	) – ATION			NEWBORN	
Father's Name Address (Village Tel: No: POST PARTU	JM EXAMIN	) – ATION		mmhg	NEWBORN Temperature	°C
Father's Name Address (Village Tel: No: POST PARTU Within I week	JM EXAMIN MOTH	ATION		kg	Temperature	°C
Father's Name Address (Village Tel: No: POST PARTU	JM EXAMIN	ATION ER BP Weight Temperature		kg 'C		°C
Father's Name Address (Village Tel: No: POST PARTU Within I week	JM EXAMIN MOTH	ATION ER BP Weight Temperature Quantity	Normal	kg °C Abnormal	Temperature Eye	°C
Father's Name Address (Village Tel: No: POST PARTU Within I week	JM EXAMIN MOTHI Vital sign and weight	ATION ER BP Weight Temperature Quantity Odour	Normal Normal	C Abnormal Abnormal	Temperature	°C
Father's Name Address (Village Tel: No: POST PARTU Within I week of delivery	JM EXAMIN MOTH Vital sign and weight Lochia	ATION ER BP Weight Temperature Quantity Odour Colour	Normal	kg °C Abnormal	Temperature Eye Cord	°C
Father's Name Address (Village Tel: No: POST PARTU Within I week of delivery	JM EXAMIN MOTH Vital sign and weight Lochia	ATION ER BP Weight Temperature Quantity Odour	Normal Normal	kg 'C Abnormal Abnormal	Temperature Eye	
Father's Name Address (Village Tel: No: POST PARTU Within I week of delivery	JM EXAMIN MOTH Vital sign and weight Lochia	ATION ER BP Weight Temperature Quantity Odour Colour BP	Normal Normal Normal	kg 'C Abnormal Abnormal Abnormal mmhg kg 'C	Temperature Eye Cord	
Father's Name Address (Village Tel: No: POST PARTU Within I week of delivery  Between 1-6 Week after	JM EXAMIN MOTH Vital sign and weight Lochia	ATION ER BP Weight Temperatur Quantity Odour Colour BP Weight Temperatur Quantity Quantity	Normal Normal Normal Normal	kg 'C Abnormal Abnormal Abnormal mmhg kg 'C Abnormal	Eye Cord Temperature	
Father's Name Address (Village Tel: No: POST PARTU Within I week of delivery  Between 1-6 Week after	JM EXAMIN MOTHI Vital sign and weight Lochia	ATION ER BP Weight Temperatur Quantity Odour EP Weight Temperatur Quantity Quantity Quantity Quantity Quantity	Normal Normal Normal Normal Normal	kg 'C Abnormal Abnormal Abnormal mmhg kg 'C Abnormal Abnormal	Eye Cord Temperature	
Father's Name Address (Village Tel: No: POST PARTU Within I week of delivery  Between 1-6 Week after	JM EXAMIN MOTHI Vital sign and weight Lochia	ATION ER BP Weight Temperatur Quantity Odour Colour BP Weight Temperatur Quantity Quantity	Normal Normal Normal Normal	kg 'C Abnormal Abnormal Abnormal mmhg kg 'C Abnormal	Eye Cord Temperature Eye	
Father's Name Address (Village Tel: No: POST PARTU Within I week of delivery  Between 1- 6 Week after Delivery	JM EXAMIN MOTH Vital sign and weight Lochia Vital sign and weight Lochia DR MOTHERS	ATION ER BP Weight Temperatur Quantity Odour Colour BP Weight Temperatur Quantity Odour Colour	Normal Normal Normal Normal Normal	kg 'C Abnormal Abnormal Abnormal mmhg kg 'C Abnormal Abnormal	Eye Cord Temperature Eye	
Father's Name Address (Village Tel: No: POST PARTU Within I week of delivery  Between 1- 6 Week after Delivery  CARE FF Antigen	JM EXAMIN MOTHI Vital sign and weight Lochia Vital sign and weight Lochia	ATION ER BP Weight Temperatur Quantity Odour Colour BP Weight Temperatur Quantity Odour Colour	Normal Normal Normal Normal Normal	kg 'C Abnormal Abnormal Abnormal mmhg kg 'C Abnormal Abnormal Abnormal	Eye Cord Temperature Eye	
Father's Name Address (Village Tel: No: POST PARTU Within I week of delivery  Between 1-6 Week after Delivery  CARE FC Antigen TT1	JM EXAMIN MOTH Vital sign and weight Lochia Vital sign and weight Lochia DR MOTHERS	ATION ER BP Weight Temperatur Quantity Odour Colour BP Weight Temperatur Quantity Odour Colour	Normal Normal Normal Normal Normal Normal Normal Normal POST PARTUM Vitamin A200,000 IU	kg "C Abnormal Abnormal Abnormal mmbg kg "C Abnormal Abnormal Abnormal	Temperature Eye Cord Temperature Eye Cord	
Father's Name Address (Village Tel: No: POST PARTU  Within I week of delivery  Between 1- 6 Week after Delivery  CARE F( Antigen TT1 TT2	JM EXAMIN MOTH Vital sign and weight Lochia Vital sign and weight Lochia DR MOTHERS	ATION ER BP Weight Temperatur Quantity Odour Colour BP Weight Temperatur Quantity Odour Colour	Normal Normal Normal Normal Normal Normal Normal Normal POST PARTUM	kg "C Abnormal Abnormal Abnormal mmbg kg "C Abnormal Abnormal Abnormal	Temperature Eye Cord Temperature Eye Cord	
Father's Name Address (Village Tel: No: POST PARTU Within I week of delivery  Between 1-6 Week after Delivery  CARE FC Antigen TT1	JM EXAMIN MOTH Vital sign and weight Lochia Vital sign and weight Lochia DR MOTHERS	ATION ER BP Weight Temperatur Quantity Odour Colour BP Weight Temperatur Quantity Odour Colour	Normal Normal Normal Normal Normal Normal Normal Normal POST PARTUM Vitamin A200,000 IU	kg 'C Abnormal Abnormal Abnormal Abnormal mmbg kg 'C Abnormal Abnormal Abnormal	Temperature Eye Cord Temperature Eye Cord	

SII-YFV Trial LEO 27754/YWF:02





#### Consent

#### Before starting confirm:

- 1. The IWC the participant is available and a certified copy has been made
- 2. The age of the participant
  - · At least 9 month but less than 12 months
- That a parent/guardian who will provide consent is:
  - ≥ 18 years of age
  - The biological parent (if no ensure a Guardianship Statement [parents both out of country or deceased] is signed first)
- Languages:
  - If <u>English</u> is to be used, the <u>literacy level</u> should be confirmed by asking the subject/parent/guardian to read and explain a section of the ICD. No impartial witness should then be present
  - If a <u>local language</u> is to be used, confirm both you and the impartial witness are fluent in the <u>language of consent</u> and that this is documented on your CV and the CV of the impartial witness.







#### **Informed Consent process**

- In the presence of an impartial witness, the field worker explains each sentence of the information sheet to the potential participant.
- The participant can ask questions, answered by the field worker or a clinician
- A clinician will then go through 10 simple questions to assess participants understanding.
- A score of 9/10 or 10/10 indicates passing. If it's 9/10, the missed question is clarified
- If the score is 8 or less, the process is repeated by a different field worker, requiring all questions to be answered correctly on the second attempt.











SII-YFV Trial LEO 27754/YWF:02

MRC Unit The Gambia as LSHTM Serum Institute of India Pvt. Ltd.

#### SII Yellow Fever Vaccine Trial Assessment of Understanding

Participant's Screening Number:	
Date of Assessment:   _ / _ _ _ /	
Fime of Assessment:   : _ : _  (24 hou	r)

Ask the participant's parent/guardian the following questions

Write the respondent's answer in the corresponding box (1 $^{\rm st}$  attempt or 2 $^{\rm nd}$  attempt) and count the correct answers

No	Question	Correct answer	1 <sup>st</sup> attempt	2 <sup>nd</sup> attempt
1	Babies in The Gambia already get vaccinated against yellow fever	т		
2	Your baby will only receive one vaccine injection at the first study visit	F		
3	You can decide if your baby gets the new yellow fever vaccine or the vaccine which is already used	F		
4	Your baby will have two blood samples during the study	т		
5	The study includes four clinic visits, including one visit which may be done over the telephone	т		
6	Your baby should continue to go to your local EPI clinic while they are in the study	F		
7	You should contact the study team if your baby is unwell during the study	т		
8	You can travel at any time during the study, and you do not need to tell us	F		
9	Once you have consented you cannot withdraw your baby from the study	F		
10	Reactions, including serious reactions can occur after any vaccine injection and could occur with the new vaccine.	т		
		Total		

V1.0 15 Apr 2022 Page 1 of 2

## **Informed Consent process**

- Once the participant passes assessment of understanding, the informed consent form is signed.
- The signed form is reviewed by a clinician.
- A second review is done by a clinical trial assistant before the copy of the consent form is given to the participant. This is to ensure that any error is corrected while the participant is still in the clinic.






# Visual aids for informed consent process

SII-YFV Trial LEO 27754/YWF:02



#### Parent/Guardian ICD completion

(Impartial Witness)




SII-YFV Trial LEO 27754/YWF:02





#### Parent/Guardian ICD completion

(English Literate)








#### Visual aids for informed consent process







V1.0 25 Aug 2022





# Concluding the enrolment visit

- After informed consent, participants proceed with trial procedures following the protocol and standard operating procedures.
- For participants who will require home visits, a home visit form is completed.
- Participants are introduced to the fieldworker who will conduct the home visit.
- Participants are given a trial-dedicated phone on a closed user group(CUG).
- Reminders and notices are attached to the infant welfare card to indicate trial participation

SII Yellow Fever Vaccine Trial





This person is currently enrolled in a vaccine trial

- 1. Please do not give any vaccines without contacting the study team
- 2. Please contact the study team if they are unwell

Contact details have been given to the parent

Thank you for your help

LEO 27754/YWF: 02

V1.0 15 Apr 2022

SII Yellow Fever Vaccin Screening number:    This person has been vaccinated		MRC Unit The Gambia	LONDON SCHOOL of HYGIENE &TROPICAL MEDICINE
Vac	cination # 1: Date   _ /		
If he/she becomes unwell or if he possible  Emergency Study Cont		clinic please contact the stu	dy team as soon as
Name:	Designation:	Tel:	
Name:	Designation:	Tel:	
Name:	Designation:	Tel:	
Further details regarding the clinic Dr E Clarke, MRC Unit The Gamb (+220) 4495442/6 Ext 4014 or 70	oia, Atlantic Road, Fajara, The C		n-
LEO 27754/YWF: 02			V1.0 15 Apr 2022

CLINIC VISIT CARD	SII Yellow Fever Vaccine Trial
The next visit to the clinic is on:	
Day:	
Date:       /       /	
LEO 27754/YWF: 02	V1.0 15 Apr 2022



# Strategies employed at the end of the trial

#### **Open days**

- Community engagement event for recruitment areas.
- Attendees: Ministry of health, traditional and religious leader and the general public.
- Feedback on completed trial results and their public health implications.
- Appreciation for community support in clinical research.







# Acknowledgements

- Prof. Ed Clarke
- Clinical trial staff
- Trial participants
- Ministry of Health, The Gambia
- CTU ISHTM and MRCG at LSHTM













# Thank you

MRC Unit The Gambia at the London School of Hygiene & **Tropical Medicine** 





